High Tower Advisors, LLC Seagen Inc. Transaction History

High Tower Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$191.51 - $216.16 $141,334 - $159,526	-738 Reduced 19.8%	2,990 $634,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $32,274 - $35,475	-172 Reduced 4.41%	3,728 $717,000
Q1 2023 May 11, 2023	SELL	$127.59 - $203.08 $807,134 - $1.28 Million	-6,326 Reduced 61.86%	3,900 $789,000
Q4 2022 Feb 08, 2023	BUY	$117.37 - $139.17 $871,706 - $1.03 Million	7,427 Added 265.34%	10,226 $1.31 Million
Q3 2022 Nov 09, 2022	BUY	$135.27 - $180.11 $173,957 - $231,621	1,286 Added 85.0%	2,799 $383,000
Q2 2022 Aug 10, 2022	SELL	$108.81 - $179.33 $2,720 - $4,483	-25 Reduced 1.63%	1,513 $270,000
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $10,047 - $13,259	84 Added 5.78%	1,538 $221,000
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $26,232 - $35,118	184 Added 14.49%	1,454 $225,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $180,911 - $215,671	1,270 New	1,270 $215,000
Q1 2021 May 10, 2021	SELL	$137.51 - $190.8 $224,828 - $311,958	-1,635 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$164.63 - $211.93 $269,170 - $346,505	1,635 New	1,635 $288,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.